HL
NTLA icon

HeadInvest LLC’s Intellia Therapeutics NTLA Stock Holding History

HeadInvest LLC’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-191
Closed -$5.62K – 528
2023
Q3 		$5.62K Buy
+191
New +$7.41K ﹤0.01% 618

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

HeadInvest LLC's NTLA Position: Q4 2023 in Review

HeadInvest LLC sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 191 shares — an estimated $5.62K sold.

HeadInvest LLC first reported a position in NTLA in Q3 2023 and held it in 1 quarter. The position peaked at $5.62K in Q3 2023. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • HeadInvest LLC reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
  • HeadInvest LLC sold 191 Intellia Therapeutics shares in Q4 2023, an estimated $5.62K.
  • HeadInvest LLC first reported a position in Intellia Therapeutics in Q3 2023 and held it in 1 quarter.
  • HeadInvest LLC's Intellia Therapeutics position peaked at $5.62K in Q3 2023.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.